Order of the National Green Tribunal in the matter of News Item titled "2 killed in blast at illegal cracker unit in Thanjavur appearing in The Hindu dated 19.05.2025". The application is registered suo-motu on the basis of the news item titled 2 killed in blast at illegal cracker unit …
Joe C Mathew India has rejected German drug major Boehringer Ingelheim's application for a pediatric form of anti-AIDS drug nevirapine bowing to objections from the country's civil society group and also to help local companies continue selling the medicine. The rejected patent application covers the syrup form of nevirapine, which …
In sharp contrast to Europe, India takes the Ranbaxy sale in its stride: maturely and realistically Enough time has passed, sufficient dust has settled, since last Wednesday's announcement of Ranbaxy's sale of control to Daiichi Sankyo, to conclude that Indian reactions to the deal have been in marked and welcome …
Biopharma major Biocon is planning to set up a dedicated greenfield facility to manufacture tablet formulations. The Bangalore-based company currently outsources this activity. Biocon is in the tablet formulation market in a small way now across the nephrology, diabetology, cardiology and oncology verticals. This segment accounts for about 10% of …
Rising research and development(R&D;) initiatives in the pharma sector has made India a more mature place for drug discovery activities than China, says a report. Further, the report prepared by US-based Ewing Marion Kauffman Foundation noted that Indian companies are playing a strategic role in early drug discovery processes due …
The Access to Medicine Foundation, based in Haarlem, the Netherlands, has developed a set of criteria to assess how ethically pharmaceutical companies perform towards developing countries. It will make its ranking available online from 16 June and hopes investors will use it to decide which companies to invest in, while …
Malvinder Went To Seek Ally For R&D; Unit, Ended Up Selling Co IT BEGAN with the Ranbaxy management looking for an investor for its R&D; unit and ended up with them finding a buyer for the parent company. And ironically, while Ranbaxy has been sold, the new owners have decided …
Signs a collaboration agreement with Safety Syringes of the U.S. safety first: Kiran Mazumdar Shaw, Chairman and Managing Director, Biocon, launching the drug delivery system in Bangalore on Wednesday. Biocon launched pre-filled syringes for delivering two life-saving drugs manufactured by it. The company has entered into a collaboration agreement with …
Even as two multinationals and an Indian pharma company fight over a generic drug to treat stomach acid, a third giant has been pulled into legal battle. Pharma biggie Wyeth had filed a patent suit against Teva Pharmaceuticals and Mumbai-based Sun Pharma for its generic drug, Protonix. Wyeth is now …
With 15 states and several union territories voicing their concern about the severe shortage of vaccines following the closure of public sector manufacturing units by the Health Ministry in January, the Government is now looking towards private players to meet the demands of the affected states. Speaking to The Indian …
The decision taken recently by the editors of 11 Indian biomedical journals to publish only the results of human clinical trials that have been registered is laudable, considering that India has become one of the most favoured countries for conducting such trials and that more and more papers are published …
The next time you buy any medicine check out for the 3d hologram symbol as most of the pharmaceuticals companies have come up with the authentic logo for the drive against fake drugs. While the health ministry in India estimates that only five per cent of the drugs sold in …
PUBLIC sector drug makers are set to regain a substantial share in the retail pharmaceutical market. These companies, which recently received fresh capital infusion from the government, are going in for a major expansion of their production capacity and product baskets. These pharmaceutical companies already have an assured market from …
Ask Govt To Immediately Increase Price Of 33 Bulk Drugs As Imported Drug Price Hike, Rupee Fall Take Toll OVER 650 drugmakers have asked the government to immediately increase the prices of 33 bulk drugs, failing which companies will have to stop manufacturing several medicines within a month or two. …
GVK Bio has entered into a research agreement with Wyeth Pharmaceuticals, a division of Wyeth, to undertake drug discovery research and generate intellectual property (IP). Based on the research output, the company would file INDs (Investigative New Drug) with the US Food & Drug Administration. The work would be largely …
Domestic drug majors and public health activists have accused research-based multinational drug companies of not providing clear information about the type or use of the potential new medicines in patent applications. The practice of using complex chemicals, or molecular formulae, in place of clear indicators as patent titles is an …
The three public sector vaccine manufacturing units in the country could be allowed to resume production if their restructuring was possible, Union Health Minister Anbumani Ramadoss said on Saturday. Dr. Anbumani told mediapersons that a committee appointed by the Union Ministry of Health would visit the three units to investigate …
Six foreign firms acquired in April AFTERa slow beginning, things are hotting up for the pharma sector on deal street. Last month, Indian drug firms acquired six overseas companies, including the $255 million acquisition of US-based Draxis Health Inc by Jubilant Organosys. Besides, the month also saw one of the …
Ranbaxy Laboratories, Dr Reddy's Laboratories, Nicholas Piramal and other pharmaceutical companies are betting on inlicensing or strategic marketing tie-ups to help grow local sales after India banned copying of patented drugs. According to analysts, Indian drug makers are forging alliances with overseas companies such as CD Pharma, Gnosis SpA, Crawford …
Who is interested in controlling spiraling drug prices or, for that matter, the skyrocketing healthcare costs? Both are interconnected although healthcare means a total package, of which drugs and pharmaceuticals form an important integral part. For medical treatment, which does not require hospitalization, the cost of drugs often takes a …
Ranbaxy has signed a collaboration agreement with US-based Merck for drug discovery and clinical development in anti-infective drugs. Ranbaxy and Merck will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates. Ranbaxy will carry out drug discovery and clinical development through Phase IIa clinical trials, with Merck conducting …
